Previous Article | Next Article 
Infection and Immunity, December 2000, p. 6917-6923, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Gene Expression and Production of Tumor Necrosis Factor Alpha,
Interleukin-1
(IL-1
), IL-8, Macrophage Inflammatory Protein 1
(MIP-1
), MIP-1
, and Gamma Interferon-Inducible Protein 10 by
Human Neutrophils Stimulated with Group B Meningococcal Outer
Membrane Vesicles
José A.
Lapinet,1,2
Patrizia
Scapini,1
Federica
Calzetti,1
Oliver
Pérez,2 and
Marco A.
Cassatella1,*
Department of Pathology, Section of General
Pathology, University of Verona, 37134 Verona,
Italy,1 and Finlay Institute, 11600, Havana, Cuba2
Received 26 July 2000/Accepted 8 September 2000
 |
ABSTRACT |
Accumulation of polymorphonuclear neutrophils (PMN) into the
subarachnoidal space is one of the hallmarks of Neisseria
meningitidis infection. In this study, we evaluated the ability
of outer membrane vesicles (OMV) from N. meningitidis B to
stimulate cytokine production by neutrophils. We found that PMN
stimulated in vitro by OMV produce proinflammatory cytokines and
chemokines including tumor necrosis factor alpha (TNF-
),
interleukin-1
(IL-1
), IL-8, macrophage inflammatory protein 1
(MIP-1
), and MIP-1
. A considerable induction of gamma
interferon (IFN-
)-inducible protein 10 (IP-10) mRNA transcripts, as
well as extracellular IP-10 release, was also observed when neutrophils
were stimulated by OMV in combination with IFN-
. Furthermore, PMN
stimulated by OMV in the presence of IFN-
demonstrated an
enhanced capacity to release TNF-
, IL-1
, IL-8, and MIP-1
compared to stimulation with OMV alone. In line with its
downregulatory effects on neutrophil-derived proinflammatory cytokines, IL-10 potently inhibited TNF-
, IL-1
, IL-8, and
MIP-1
production triggered by OMV. Finally, a neutralizing
anti-TNF-
monoclonal antibody (MAb) did not influence the release of
IL-8 and MIP-1
induced by OMV, therefore excluding a role
for endogenous TNF-
in mediating the induction of chemokine
release by OMV. In contrast, the ability of lipopolysaccharide from
N. meningitidis B to induce the production of IL-8 and
MIP-1
was significantly inhibited by anti-TNF-
MAb. Our results
establish that, in response to OMV, neutrophils produce a
proinflammatory profile of cytokines and chemokines which may not only
play a role in the pathogenesis of meningitis but may also contribute
to the development of protective immunity to serogroup B meningococci.
 |
INTRODUCTION |
Polymorphonuclear neutrophils (PMN)
are natural effector cells mediating antimicrobial defense via the
release of toxic oxygen intermediates and lytic enzymes
(15a). Nevertheless, the studies conducted in many
laboratories during the last decade have clearly established that the
release of cytokines constitutes another important aspect of the
biology of PMN (reviewed in reference 11). The cytokines that PMN
produce include, for instance, interleukin-1
/
(IL-1
/
), IL-1
receptor antagonist, IL-12, tumor necrosis factor-alpha (TNF-
),
transforming growth factor
, vascular endothelial growth factor, and
chemokines such as IL-8, macrophage inflammatory protein 1
/
(MIP-1
/
), and gamma interferon (IFN-
)-inducible protein 10 (IP-10) (11). Broadly speaking, these mediators exert not only pro- or anti-inflammatory activities but also important
immunoregulatory actions (8). Since PMN usually represent
the first cell type encountering, and interacting with, the etiological
agent in an inflammatory context, the fact that they can synthesize and
release a wide array of cytokines should lead to a reconsideration of their role in immunoregulation and physiopathology.
Bacterial meningitis is among the most dangerous infections of children
and young adults because of the rapidity of onset, the high mortality
rate, devastating sequelae, and its tendency to spread and cause
outbreaks (13). Neisseria meningitidis, commonly
known as meningococcus, is the most important cause of purulent
meningitis and septicemia worldwide (38). Meningocci are
classified into different serogroups, serotypes, and
immunotypes according to their capsular polysaccharides, outer
membrane proteins, and lipopolysaccharides (LPS), respectively (1,
15, 24). The virulent strains of N. meningitidis
responsible for 90% of meningoccoccal diseases correspond to
serogroups A, B, and C, with serogroup B meningococci being the most
common cause of meningococcal diseases in many countries
(30). The hallmark of bacterial meningitis is the entry of
an enormous number of leukocytes into the subarachnoid space, with a
clear neutrophil predominance during the initial phases, followed by a
monocyte increase later in the course of the disease (25).
Leukocytes are considered to initiate and propagate brain injury
through the release of reactive oxygen and nitrogen metabolites,
proteases, and/or toxic cytokines. Interestingly, very little is known
regarding the capacity of human neutrophils to generate cytokines
in response to N. meningitidis. To address this issue, we
investigated whether human PMN produce proinflammatory cytokines and
chemokines in response to bacterial components derived from serogroup B
meningococci. In particular, we used lipo-oligosaccharide-reduced outer membrane vesicles (OMV) from an epidemic Cuban strain of N. meningitidis (CU385, B:4:P1,19,15), which is
the major component of the Cuban vaccine called VA-MENGOC-BC
(16, 17, 35). OMV consists of defined amounts of purified
OMP from serogroup B N. meningitidis enriched with proteins
from the high-molecular-mass protein complex (65 to 95 kDa), containing
also a controlled proportion of LPS and phospholipids. In addition to
OMV, the vaccine contains purified capsular polysaccharide of serogroup
C meningococcus, and both are adsorbed on aluminum hydroxide (16,
17, 35). Indeed, although polysaccharide-based vaccines are
available and offer a high protection against N. meningitidis serogroups A and C in children older than 2 years,
this principle cannot be applied to the B serogroup because of the poor
immunogenicity of polysaccharide B in humans (42). A
randomized double-blind placebo controlled trial and
observational studies carried out with VA-MENGOC-BC have
demonstrated an efficacy and effectiveness of >83% against serogroup
B meningococci (35, 36).
Herein, we report that human neutrophils, upon incubation with OMV,
release both proinflammatory cytokines, such as TNF-
and IL-1
,
and chemokines, such as IL-8, MIP-1
, and IP-10. These findings
suggest that neutrophil-derived cytokines and chemokines might
represent an early event during the course of meningitis.
 |
MATERIALS AND METHODS |
Cell purification and culture.
Highly purified granulocytes
(>98% purity) and peripheral blood mononuclear cells (PBMC) were
isolated under endotoxin-free conditions from the buffy coats of
healthy donors, as previously described (4). The granulocyte
populations contained usually <4% eosinophils (n = 42), as revealed by May-Grunwald-Giemsa staining. Immediately after
purification, cells were usually suspended in RPMI 1640 medium
supplemented with 10% low-endotoxin fetal calf serum (FCS; <0.009
ng/ml; Seromed; Biochrom KG, Berlin, Germany) and stimulated with OMV.
The OMV were prepared as previously described (16, 17).
Briefly, N. meningitidis strain B:4:P1,19,15 was grown until
early stationary phase, and OMV were extracted by using 0.1 M Tris-HCl
(pH 8.6), 10 mM EDTA, and 0.5% (wt/vol) deoxycholate. The OMV were
purified by sequential centrifugation steps at 20,000 × g for 30 min. Following ultracentrifugation at 125,000 × g for 2 h, the OMV were pelleted and homogenized in
phosphate-buffered saline (PBS; pH 7.2) with 3% (wt/vol) sucrose
(16, 17). The concentration of LPS (from N. meningitidis B:4:P1,19,15; L3,7,9) inserted into the lipid bilayer
of OMV preparation ranges from 1 to 4% (35). Preliminary
dose-response experiments established that 5-µg/ml concentration of
OMV represented the optimal concentration to stimulate cytokine release
by PMN. In selected experiments, cells were costimulated with OMV or
200 ng of LPS per ml from N. meningitidis (strain
B:4:P1,19,15; L3,7,9; prepared at the Finlay Institute, Havana, Cuba)
in combination with either 100 U of IFN-
(Hoffman-La Roche, Basel,
Switzerland) (27) per ml, or 10 ng of IL-10 (Peprotech Inch,
Nutley, N.J. (3) per ml. In other experiments, neutrophils
were pretreated for 30 min with either 10 µg of polymyxin B sulfate
(PMX) (Sigma) per ml or neutralizing monoclonal antibodies (MAbs)
against TNF-
(B.154.2) and isotype-matched control MAb for B.154.2,
as previously described (6). Cells were then plated at
5 × 106/ml either in 12-well tissue culture plates
(BioWhittaker) or in polystyrene flasks (Greiner, Nurtingen, Germany)
at 5 × 106/ml and cultured at 37°C in a 5%
CO2 atmosphere. At the times indicated, cell supernatants
were harvested and stored at
20°C, whereas the pellets were used
for RNA extraction. All reagents used were of the highest available
grade and were dissolved in pyrogen-free water for clinical use
(3, 4, 6, 27, 33).
RNA isolation, Northern blot analysis, and RPA.
Total RNA
from PMN and PBMC was extracted, by the guanidinium isothiocyanate
method, usually from 6 × 107 to 7 × 107 PMN and 2 × 107 to 3 × 107 PBMC per condition, and then analyzed by either
Northern blotting (4, 6) or by RNase protection assay (RPA)
(33). For Northern blot experiments, the filters were
hybridized using TNF-
and actin cDNA fragments, previously
32P labeled using a Ready-To-Go DNA labeling kit
(Pharmacia, Uppsala, Sweden). For the RPA experiments, the RiboQuantTM
hcK-2 and hcK-5 Human Multi-Probe Template Sets were used according to
the manufacturer's instructions (PharMingen International, San Diego,
Calif.). The extent of hybridization was quantitatively analyzed in an
InstantImager (Packard Instruments, Meriden, Conn.) and plotted after
actin normalization.
Cytokine measurements.
Antigenic IL-8 was measured in the
cell supernatants by using a double-ligand enzyme-linked immunosorbent
assay (ELISA) method (with a 20-pg/ml detection limit) (6).
The levels of TNF-
and IL-1
were determined in the cell
supernatants by using ELISA kits purchased from Endogen (Woburn, Mass.;
5-pg/ml detection limit) and Diaclone (Cedex, France; 15-pg/ml
detection limit), respectively. Antigenic MIP-1
and IP-10 were
measured in the cell supernatants by using specific ELISAs developed
with antibodies purchased from R&D Systems (Minneapolis, Minn.).
Briefly, flat-bottomed 96-well plates (MaxiSorp 439454; Nunc) were
coated with 50 µl of a 1-µg/ml concentration of polyclonal
anti-human MIP-1
or IP-10 antibodies (MAb271-NA and MAb266-NA,
respectively) per well in PBS (pH 7.4) and then incubated overnight.
After four washings of the plates with PBS-0.05% Tween 20 (pH. 7.4)
(washing buffer), 150 µl of blocking buffer (PBS containing 1%
bovine serum albumin [BSA], 5% sucrose, and 0.05% NaN3)
was added per well, followed by a 1-h incubation. Plates were then
rinsed with washing buffer before the addition of 50 µl of either
MIP-1
and IP-10 standards (30 to 960 pg/ml, diluted in RPMI 1640 with 10% FCS) or cell supernatants per well and subsequently incubated
for 2 h. Biotinylated anti-human MIP-1
antibody (BAF271) or
anti-human IP-10 antibody (BAF266) at 0.5 µg/ml (50 µl/well) in
Tris-buffered saline solution (20 mM Trizma base, 150 mM NaCl)
containing 0.1% BSA-0.05% Tween 20 (pH 7.3) was added after washing
the plates, and the mixtures were then incubated for 2 h. Plates
were washed before the addition of 50 µl of 1:10,000
streptavidin-horseradish peroxidase (Zymed, San Francisco, Calif.) per
well in TBS and incubated for 20 min. After a washing with
TBS-0.05% Tween 20 (pH 7.4), 20- to 30-min chromogenic reaction was
performed using 1:1 mixture of H2O2 and tetramethylbenzidine (Medix Biotech, San Carlos, Calif.). The reaction
was stopped with 0.5 M H2SO4, and the
absorbance at 450 nm was measured. All of the incubation steps were
performed at room temperature. The detection limit of these MIP-1
and IP-10 ELISAs were 30 and 60 pg/ml, respectively.
Statistical analysis.
The data are expressed as the
means ± the standard error of the mean (SEM). Statistical
evaluation was performed by using the Student's t test for paired data
and was considered significant if the P values were <0.05.
 |
RESULTS |
TNF-
mRNA expression and production by PMN stimulated with
OMV.
In the first series of experiments, we examined the capacity
of neutrophils to produce TNF-
in response to OMV. For this purpose,
purified populations of PMN were cultured in the absence or the
presence of OMV. At the indicated times, total RNA was isolated for
Northern blot analysis, whereas cell supernatants were harvested for
TNF-
detection by ELISA. Autologous PBMC were also isolated and
stimulated as the PMN. Figure 1A shows
that treatment of PMN with OMV resulted in a time-dependent induction of TNF-
mRNA that reached maximum levels at 2 h and then
declined. Interestingly, the levels of TNF-
mRNA accumulated in
PMN stimulated for 2 h with OMV were higher than those observed in
autologous PBMC treated under identical conditions (Fig. 1A). The
latter observation argues against the possibility that the TNF-
mRNA found in stimulated neutrophils is attributable to the minimal contamination by PBMC. In accord with the Northern blot data, culture of PMN with OMV stimulated a detectable extracellular production of TNF-
protein that began as early as after 2 h
(P < 0.001, n = 5) and continued to
progressively rise for up to 21 h (P < 0.005, n = 6) (Fig. 1B). Cell-associated TNF-
was found only in OMV-stimulated PMN and not in freshly isolated or
medium-treated cells, thus excluding the possibility of a TNF-
release from preformed stores (not shown). Ability of OMV to induce the
release of TNF-
was dose dependent (being already evident at 1 µg/ml) and was not inhibited by PMX, either at the level of mRNA
or at the level of protein production (data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of OMV on the induction of TNF- production by
human neutrophils. (A) Comparative ability of neutrophils and PBMC to
express TNF- mRNA in response to OMV. Samples of 7 × 107 PMN were cultured in the presence or absence of 5 µg
of OMV per ml. After the times indicated, total RNA was extracted and
Northern blot analysis for TNF- and actin transcripts was performed.
Then, 10 µg of total RNA was loaded per each gel lane. The figure
shows the results of one representative experiment out of two performed
with identical results. (B) Time course of TNF- release by
OMV-stimulated neutrophils. PMN (5 × 106/ml) were
stimulated with OMV for the times indicated before determining the
levels of TNF- in the cell supernatants by ELISA. The figure shows
the mean values ± the SEM for each time point, which were
obtained from at least five experiments performed under the same
conditions. The asterisks represent significant differences between
OMV-treated and control PMN: ***, P < 0.005;
****, P < 0.001.
|
|
Effect of IFN-
and IL-10 on the production of TNF-
by
OMV-stimulated PMN.
Since IFN-
and IL-10 were previously shown
to modulate cytokine gene expression and release in LPS-treated PMN
(5, 7, 10), we examined their effects on the release of
TNF-
by OMV-stimulated PMN. Neither IFN-
nor IL-10 used alone
stimulated TNF-
mRNA expression, nor did they influence TNF-
secretion by PMN (6, 27). In contrast, PMN treated with
IFN-
plus OMV for 21 h secreted approximately ninefold more
TNF-
protein than PMN stimulated with OMV alone (P < 0.001, n = 6), whereas PMN treated with IL-10 were
dramatically inhibited in their capacity to release TNF-
(by 85 ± 13%, P < 0.005, n = 4).
IL-1
production by PMN stimulated with OMV.
Subsequently,
we decided to investigate whether neutrophils synthesize and release
IL-1
protein in response to OMV. Preliminary experiments indicated
in fact that, in the presence of OMV, IL-1
mRNA transcripts
markedly increased in PMN by 2 to 3 h and then declined to almost
disappear over the next 18 h (data not shown). Figure
2A shows that neutrophils did not
spontaneously release IL-1
into the culture supernatants but they
did secrete IL-1
following treatment with OMV in a time-dependent
manner (Fig. 2A). Similarly to what we observed for TNF-
, the
release of IL-1
by OMV-stimulated PMN was significantly enhanced by
IFN-
and inhibited by IL-10 (Fig. 2B).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of OMV on the induction of IL-1 production by
human neutrophils. (A) Time course release of IL-1 by neutrophils
stimulated with OMV. PMN were incubated with or without 5 µg of OMV
per ml for up to 21 h at 37°C, and the resulting cell
supernatants were processed for the determination of IL-1 levels by
ELISA. The results are expressed as the mean ± the SEM for each
time point of duplicated determinations from five independent
experiments. The asterisks represent significant differences between
OMV-treated and control PMN, i.e., "***" indicates
P < 0.005. (B) Effect of IFN- and IL-10 on the
production of IL-1 in OMV-simulated PMN. PMN were preincubated with
or without 100 U of IFN- or 10 ng of IL-10 per ml for 30 min and
then cultured for 21 h after the addition of 5 µg of OMV per ml.
The bars report the mean values ± the SEM of the percentage of
enhancement or inhibition of IL-1 release by OMV-stimulated PMN, as
exerted by IFN or IL-10, respectively, calculated from five
experiments. The percent values were calculated from the difference in
the amount of IL-1 produced in the absence or presence of IFN- or
IL-10. *, P < 0.05; ***, P < 0.005.
|
|
Chemokine gene expression and production by PMN stimulated with
OMV.
Because it is well established that, in addition to TNF-
,
PMN are able to express and secrete a number of chemokines (8, 11), we investigated whether PMN challenged by OMV could produce IL-8, MIP-1
/
, and IP-10. Initially, we evaluated by RPA chemokine mRNA expression in PMN and PBMC stimulated for 3 h with
OMV in the presence or absence of IFN-
. Figure
3A shows that IL-8, MIP-1
, and
MIP-1
mRNA levels were dramatically increased by OMV in either PMN or PBMC. Time course analyses in OMV-treated neutrophils
revealed very similar patterns for IL-8, MIP-1
, and MIP-1
mRNA expression, all of which displayed maximum levels at 3 h
after stimulation and a gradual decrease thereafter (Fig. 3B). IP-10
mRNA was also induced in PMN, but only if neutrophils were
stimulated with OMV in combination with IFN-
(Fig. 3A). The latter
cytokine was per se ineffective (Fig. 3A), as previously
described (9). In contrast, IFN-
alone represented a very
potent stimulus for IP-10 mRNA accumulation in PBMC (Fig. 3A),
its effect being partially suppressed by the presence of OMV
(Fig. 3A). Furthermore, unlike neutrophils, PBMC also
accumulated RANTES transcripts, even though their levels did
not change under any conditions (Fig. 3A). Again, these observations indicate that the chemokine mRNA found in PMN is not attributable to their minimal contamination with PBMC or eosinophils.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 3.
Chemokine mRNA expression in OMV-stimulated neutrophils.
(A) Purified populations of PMN and PBMC isolated from the same donor
were cultured with or without 5 µg of OMV per ml. Total RNA was then
extracted, and chemokine mRNA levels were assessed by RPA. Then, 10 µg of total RNA was used for each condition. The autoradiography
shown is representative of three different experiments. (B) Time course
of chemokine mRNA expression. PMN were incubated with or without 5 µg
of OMV per ml. At the time points indicated, the total RNA was
extracted and analyzed for IL-8, MIP-1 , and MIP-1 mRNA expression
by RPA. Hybridization signals were quantitatively analyzed in an
InstantImager, as described in Materials and Methods. The experiment
depicted in this figure is representative of two.
|
|
Next, we investigated whether OMV-treated PMN could also
release IL-8, MIP-1

, and IP-10 proteins by utilizing specific
ELISAs.
Kinetic experiments demonstrated that in OMV-treated PMN,
significant
levels of IL-8 appeared in the supernatants as early as
2 h after
of stimulation (
P < 0.05,
n = 5), before progressively accumulating
for up to
21 h (
P < 0.005,
n = 5) (Fig.
4A). In contrast, MIP-1
production in
response to OMV, although significant already after
2 h
(
P < 0.05,
n = 5), rapidly increased
at later time points
(Fig.
4B). As in the case of TNF-

release, the
ability of OMV
to trigger the production of IL-8 and MIP-1

was not
inhibited
by PMX (data not shown). Surprisingly, the yields of IL-8 and
MIP-1

produced in response to 200 ng of LPS per ml from serogroup
B
N. meningitidis was not inhibited by PMX (data not shown).
However,
the latter observation is in line with the notion that the
PMX-mediated
inhibition of LPS-induced cytokine secretion depends on
the origin
of LPS (
12).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Kinetics of IL-8 and MIP-1 production by
OMV-stimulated neutrophils. PMN were stimulated with 5 µg of OMV per
ml for the times indicated. IL-8 (A) and MIP-1 (B) levels were then
determined in the cell supernatants by ELISA. For each cytokine, the
figure shows the mean value ± the SEM of duplicate assays for
each time point, each obtained from five experiments performed under
the same conditions. The asterisks represent significant differences
between OMV-treated and control PMN: *, P < 0.05;
**, P < 0.01; and ***, P < 0.005.
|
|
Neutrophils were also found to release considerable amounts
of IP-10, but only when they were cultured with OMV in association
with IFN-

for 21 h (
P < 0.005,
n = 5) (Fig.
5A).
Interestingly,
the production of IP-10 by PMN was delayed in comparison
with
those of IL-8 or MIP-1

, since >80% of the total antigenic
IP-10
was released between 5 and 21 h (Fig.
5A). In contrast to
PMN,
PBMC treated with IFN-

alone released amounts of IP-10
higher
than those detected in IFN-

plus OMV-treated cells (Fig.
5B),
which is in line with the pattern of IP-10 mRNA expression shown
in
Fig.
3A.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Extracellular production of IP-10 by stimulated PMN. (A)
PMN were stimulated with 5 µg of OMV per ml in the presence or
absence of 100 U of IFN- per ml. Cell supernatants were collected at
the indicated time points, and IP-10 protein levels were measured using
a specific ELISA. Values are expressed as the means ± the SEM of
averaged duplicate determinations for each time point, each obtained
from five experiments. The asterisks represent significant differences
between OMV plus IFN- -treated and control PMN (***,
P < 0.005). (B) PBMC (5 × 105/ml)
from autologous donors were stimulated with 5 µg of OMV per ml in the
presence or absence of 100 U of IFN- per ml. Cell supernatants were
collected after 21 h, and antigenic IP-10 was then measured by
ELISA. The figure shows the mean values ± the SEM of duplicate
assays for each condition obtained from three independent
experiments.
|
|
Effects of IFN-
and IL-10 on chemokine production by
OMV-stimulated PMN.
We then determined whether IFN-
and IL-10
had any effect on the production of IL-8 and MIP-1
by OMV-stimulated
PMN. Neither IFN-
nor IL-10, used alone, stimulated any secretion of
IL-8 and MIP-1
by PMN (6, 18, 19, 27). The yields of IL-8 and MIP-1
recovered after 21 h from PMN stimulated with IFN-
plus OMV were higher than those recovered from PMN treated with OMV
alone (by 382 ± 197%, P < 0.01, n = 8 for IL-8, and by 45 ± 19%,
P < 0.05, n = 8 for MIP-1
) (Fig.
6A). In contrast, the yields of IL-8 and
MIP-1
detected after 21 h of OMV stimulation were markedly
suppressed by IL-10 (by 52 ± 13%, P < 0.01, n = 8 for IL-8; by 50 ± 8%, P < 0.01, n = 8 for MIP-1
) (Fig. 6B).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of IFN- and IL-10 on the release of IL-8 and
MIP-1 induced by OMV. (A) PMN were preincubated for 30 min with or
without 100 U of IFN- per ml and then cultured for 21 h after
the addition of OMV before determining the chemokine release. The
figure shows the mean values ± the SEM of the percentage of
enhancement of chemokine release determined by IFN- treatment.
Percent values were calculated from the difference in the amount of
cytokine produced in the absence or presence of IFN- calculated from
eight experiments. The values of the constitutive cytokine secretion
were not subtracted. The asterisk represents significant differences
between IFN- -treated and control PMN (*, P < 0.05; **, P < 0.01). (B) PMN were preincubated
with or without 10 ng of IL-10 per ml for 30 min and then cultured for
up to 21 h after the addition of OMV. The cell supernatants were
then collected, and the levels of IL-8 and MIP-1 protein were
determined. Values are the mean ± the SEM of the percentage of
IL-10 inhibition, as calculated from eight independent experiments for
IL-8 and MIP-1 , respectively. The asterisks represent significant
differences between IL-10-treated and control PMN (*,
P < 0.05; **, P < 0.01).
|
|
Lack of an autocrine role of TNF-
in the stimulation of IL-8 and
MIP-1
production by OMV.
TNF-
represents a very efficient
stimulus for IL-8 and MIP-1
release by PMN (2, 6), and it
has been previously shown to play an autocrine role for IL-8 and
MIP-1
/
expression in neutrophils stimulated with LPS from
Escherichia coli (2, 6, 19, 27). Therefore, we
evaluated the possibility that the expression of IL-8 and MIP-1
induced by OMV was driven by the TNF-
induced early after OMV
stimulation (Fig. 1B). These experiments revealed that neutralizing
anti-TNF-
MAb did not inhibit the yields of IL-8 (n = 3) or MIP-1
(n = 3) measured after 21 h of stimulation with OMV (Fig. 7). In
contrast, the production of IL-8 or MIP-1
induced by LPS from
N. meningitidis strain B was significantly reduced by the
anti-TNF-
MAb (by 21 ± 12%, P < 0.05, n = 3 for IL-8; by 19 ± 7%, P < 0.05, n = 3 for MIP-1
) (Fig. 7). Incubation of
neutrophils with isotype-matched antibodies had no effect on the
production of chemokines by stimulated neutrophils (not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of neutralizing anti-TNF- MAb on PMN-derived
IL-8 and MIP-1 induced by OMV. PMN were stimulated with 5 µg of
OMV or 200 ng of LPS per ml from N. meningitidis strain B
for 21 h in the presence or absence of anti-TNF- neutralizing
antibodies. Cell supernatants were then analyzed for IL-8 and MIP-1
accumulation into the supernatants. The figure shows the mean
values ± the SEM of the percentage of enhancement or suppression
of chemokine release as determined by measuring the levels of
anti-TNF- MAb. The percent values were calculated from the
difference in the amount of cytokine produced in the absence or
presence of anti-TNF- MAb, as determined from three experiments. The
asterisks represent significant differences between anti-TNF-
MAb-treated and control PMN (*, P < 0.05).
|
|
 |
DISCUSSION |
The results of this study demonstrate that human PMN respond to
stimulation with OMV from serogroup B N. meningitidis by
producing several cytokines and chemokines, including TNF-
, IL-1
,
IL-8, and MIP-1
/
, as well as IP-10, when costimulated with
IFN-
. As previously shown in LPS-treated PMN (2, 6, 10, 18, 27,
41), the production of TNF-
, IL-1
, IL-8, and MIP-1
/
induced by OMV was greatly potentiated by IFN-
and dramatically suppressed by IL-10. By contrast, anti-TNF-
MAbs had no influence on
the capacity of OMV to induce the release of either IL-8 or MIP-1
,
whereas they significantly inhibited the stimulation determined by LPS
from N. meningitidis serogroup B used at the concentrations present in our OMV preparation or from E. coli
(6). These findings not only indicate that endogenous
TNF-
does not play any autocrine role in inducing IL-8 and MIP-1
in OMV-treated PMN but also demonstrate that the effects attributed to
OMV are not caused by the small amounts of LPS inserted into in the OMV
complex. Nevertheless, the possibility that LPS contributes to
stimulate PMN is not excluded. Although we cannot exclude the role of
other endogenous factors produced in response to OMV, for example
IL-1
and IL-1
, our study strongly indicate that OMV (containing
LPS) and soluble LPS affect PMN cytokine production by distinct
pathways. Whether OMV interacts with a specific receptor on neutrophils
or is simply internalized by fluid-phase pynocytosis remains to be
determined. In this context, it is important to remember that the OMV
complex has a diameter of 70 ± 20 nm and that such a particulate
structure is likely to be phagocytosed.
It is well established that in humans, classic proinflammatory
cytokines, including TNF-
, IL-1, and IL-12, are present in the
cerebrospinal fluid (CSF) during meningitis (20, 21, 32). In
addition, CXC and CC chemokines, including IL-8, GRO-
, MIP-1
, and
MIP-1
, have also been found in the CSF of such patients, including
those infected with N. meningitidis (37).
Furthermore, a critical pathogenetic role of cytokines and chemokines
has been carefully established by using several different experimental models of bacterial meningitis. For example, while injection of TNF-
and IL-1 directly into the CSF results in an inflammatory response,
antibodies neutralizing TNF-
and IL-1 are able to mitigate the
extent of inflammation in experimental meningitis (29, 31, 40). Other evidence indicates that the recruitment of leukocytes in infectious meningitis involves the intrathecal production of chemokines (22). Interestingly, the majority of cytokines
and chemokines are present at high concentrations in the CSF during meningitis, whereas they are undetectable in plasma, suggesting that
cytokines are produced locally (26, 28, 40). Potential sources of cytokines and chemokines have been identified during meningeal inflammation, both within the brain parenchyma and in meningeal inflammatory cells. Indeed, endothelial cells, microglial cells, astrocytes, and infiltrating monocytes are considered to be the
major origin sites of cytokines and chemokines (39), but
only little attention has been devoted to the role of PMN, the hallmark
of early events of meningeal infections. For instance, in an
experimental model in which mice were intracerebrally infected with
Listeria monocytogenes, the majority (80%) of the invading cells at 24 h postinfection were PMN (34). However,
after 72 h, >50% of the cellular infiltrate consisted of
monocytes. As measured by in situ hybridization, it was shown that
MIP-1
and MIP-1
genes were expressed in infiltrating cells
already after 12 h and that PMN were the main source of the two
chemokines in the early phases of the disease (34). On the
other hand, in the later phases, both PMN and monocytes were shown to
produce MIP-1
and MIP-1
(34). MIP-1
, MIP-1
, and
MIP-2 were also found in the CSF of the infected mice and contributed
to CSF-mediated chemotaxis on PMN and mononuclear cells in vitro
(34). More recently, in an infant rat model of
Haemophilus influenzae meningitis, elevated mRNA
expression for MIP-2, MIP-1
, macrophage chemotactic protein-1
(MCP-1), and RANTES was found, with kinetics paralleling those of inflammatory cells and disease severity (14). PMN
and monocytes/macrophages were the main sources of MIP-2 and MIP-1
mRNA in the brains of mice with H. influenzae meningitis
(14). Neutrophils and monocytes/macrophages were the main
sources of MIP-2 and MIP-1
mRNA in the brains of mice with
H. influenzae type b meningitis (14).
Importantly, treatment with neutralizing antibodies against MIP-2,
MIP-1
, and MCP-1 significantly reduced the recruitment of leukocytes
into the brain in response to H. influenzae type b
inoculation, suggesting that leukocyte accumulation was dependent, at
least in part, on the production of these chemokines (MIP-2,
MIP-1
, and MCP-1) (14). The capacity of PMN to
express the genes for many chemokines in response to N. meningitidis products, documented in our study, not only extend
the data described above but also highlights the potential role
of PMN in mediating a leukocyte influx through the release of various chemokines.
In conclusion, the results presented here also provide new insights for
a better understanding of the cellular mechanisms whereby VA-MENGOC-BC,
the Cuban OMV-based vaccine, exerts its immunogenic and protective
effects (23, 35). Presumably, all the cytokines and
chemokines produced by PMN in response to OMV, as shown here, play a
role in the cellular responses induced at the level of both the
inductive and effector arms of the immune response. Neutrophils rapidly
migrate in large numbers at the infection or immunization sites. The
fact that they also serve as a cytokine source may contribute to the
generation of the conditions necessary for both the recruitment and
activation of monocytes, dendritic cells, and lymphocytes and the
development of a protective immunogenic response.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from M.U.R.S.T. (40 and 60%
funds), The Progetto Sanità Fondazione CARI-VR-VI-BL-AN, and The
Consorzio per lo Studio e lo Sviluppo degli Studi Universitari di
Verona. José A. Lapinet is a fellow of the International Center for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. Patrizia Scapini was supported by a fellowship from Fondazione Italiana
per la Ricerca sul Cancro (FIRC).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Section of General Pathology, Strada Le Grazie 4, I-37134 Verona, Italy. Phone: 39-045-8027130. Fax: 39-045-8027127. E-mail: MCNCSS{at}borgoroma.univr.it.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Abdillahi, H., and J. T. Poolman.
1987.
Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies.
FEMS Microbiol. Lett.
48:367-371[CrossRef].
|
| 2.
|
Bliss, S. K.,
A. J. Marshall,
Y. Zhang, and E. Y. Denkers.
1999.
Human polymorphonuclear leukocytes produce IL-12, TNF- , and the chemokines macrophage-inflammatory protein-1 and -1 in response to Toxoplasma gondii antigens.
J. Immunol.
162:7369-7375[Abstract/Free Full Text].
|
| 3.
|
Bovolenta, C.,
S. Gasperini,
P. McDonald, and M. A. Cassatella.
1998.
High-affinity receptor for IgG (Fc gamma RI/CD64) gene and STAT protein binding to the IFN-gamma response region (GRR) are regulated differentially in human neutrophils and monocytes by IL-10.
J. Immunol.
160:911-919[Abstract/Free Full Text].
|
| 4.
|
Cassatella, M. A.,
F. Bazzoni,
R. M. Flynn,
S. Dusi,
G. Trinchieri, and F. Rossi.
1990.
Molecular basis of interferon- and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components.
J. Biol. Chem.
265:20241-20246[Abstract/Free Full Text].
|
| 5.
|
Cassatella, M. A., and G. Berton.
1992.
Modulation of neutrophil functions by IFN , p. 387-398.
In
S. Baron (ed.), Interferon: principles and application. UTMB, Galveston, Tex.
|
| 6.
|
Cassatella, M. A.,
L. Meda,
S. Bonora,
M. Ceska, and G. Constantin.
1993.
Interleukin 10 inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of TNF and IL-1 in mediating the production of IL-8 triggered by lipopolysaccharide.
J. Exp. Med.
178:2207-2211[Abstract/Free Full Text].
|
| 7.
|
Cassatella, M. A.
1995.
The production of cytokines by polymorphonuclear neutrophils.
Immunol. Today
16:21-26[CrossRef][Medline].
|
| 8.
|
Cassatella, M. A.
1996.
Cytokines produced by polymorphonuclear neutrophils: molecular and biological aspects.
Landes Co., Berlin, Germany.
|
| 9.
|
Cassatella, M. A.,
S. Gasperini,
F. Calzetti,
A. Bertagnin,
A. D. Luster, and P. P. McDonald.
1997.
Regulated production of the interferon- -inducible protein-10 (IP-10) chemokine by human neutrophils.
Eur. J. Immunol.
27:111-115[Medline].
|
| 10.
|
Cassatella, M. A.
1998.
The neutrophil: one of the cellular targets of interleukin-10.
Int. J. Clin. Lab. Res.
28:148-161[CrossRef][Medline].
|
| 11.
|
Cassatella, M. A.
1999.
Neutrophil-derived proteins: selling cytokines by the pound.
Adv. Immunol.
73:369-509[Medline].
|
| 12.
|
Cavaillon, J. M., and N. Haeffner-Cavaillon.
1986.
Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin.
Mol. Immunol.
23:965-969[CrossRef][Medline].
|
| 13.
|
De Voe, I. W.
1982.
The meningococcus and mechanism of pathogenicity.
Microbiol. Rev.
46:162-170[Free Full Text].
|
| 14.
|
Diab, A.,
H. Abdalla,
H. L. Li,
F. D. Shi,
J. Zhu,
B. Hojberg,
L. Lindquist,
B. Wretlind,
M. Bakhiet, and H. Link.
1999.
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1 attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis.
Infect. Immun.
67:2590-2601[Abstract/Free Full Text].
|
| 15.
|
Frasch, C. E.,
W. D. Zollinger, and J. T. Poolman.
1985.
Serotype antigens of Neisseria meningitidis and a proposal scheme for designation of serotypes.
Rev. Infect. Dis.
7:504-510[Medline].
|
| 15a.
|
Gabrilovich, D. (ed.).
1999.
The neutrophils: new outlook for old cells.
Imperial College Press, London, United Kingdom.
|
| 16.
| Huergo C., G. Sierra Gonzalez, M. M. Gutierrez
Vazquez, G. Bisset Jorrin, L. G. Garcia Imia, G. de la Caridad
Puentes Rizo, M. del Carmen Sampedro Herrera, F. Sotolongo Padron,
E. X. Le Riverend Morales, and M. A. Galguera Dominguez.
1988. European patent 885900077.8.
|
| 17.
| Huergo, C. C., V. G. Sierra Gonzalez, et
al. 1997. U.S. patent 5,597,572.
|
| 18.
|
Kasama, T.,
R. M. Strieter,
N. W. Lukacs,
M. D. Burdick, and S. L. Kunke.
1994.
Regulation of PMN-derived chemokine expression by IL-10.
J. Immunol.
152:3559-3569[Abstract].
|
| 19.
|
Kasama, T.,
R. M. Strieter,
N. W. Lukacs,
P. M. Lincoln,
M. D. Burdick, and S. L. Kunkel.
1995.
Interferon modulates the expression of neutrophil-derived chemokines.
J. Investig. Med.
43:58-67[Medline].
|
| 20.
|
Kornelisse, R. F.,
H. F. Savelkoul,
P. H. Mulder,
M. H. Suur,
P. J. van der Straaten,
A. J. van der Heijden,
R. N. Sukhai,
K. Hahlen,
H. J. Neijens, and R. de Groot.
1996.
Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis.
J. Infect. Dis.
173:1498-1502[Medline].
|
| 21.
|
Kornelisse, R. F.,
C. E. Hack,
H. F. Savelkoul,
T. van der Pouw Kraan,
W. C. Hop,
G. van Mierlo,
M. H. Suur,
H. J. Neijens, and R. de Groot.
1997.
Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis.
Infect. Immun.
65:977-881.
|
| 22.
|
Lahrtz, F.,
L. Piali,
K. S. Spanaus,
J. Seebach, and A. Fontana.
1998.
Chemokines and chemotaxis of leukocytes in infectious meningitis.
J. Neuroimmunol.
85:33-43[CrossRef][Medline].
|
| 23.
|
Lastre, M.,
J. Lapinet,
L. Baly,
M. Camaraza,
M. Diaz,
C. Zayas,
T. Leyva,
G. Sierra, and O. Perez.
1998.
Opsonophagocytic and bactericidal activities and anti-EMV IgG antibodies response induced after vaccination with VA-MENGOC-BC, p. 220.
In
X. Nassif, M. Quentin-Millet, and M. Taha (ed.), Proceedings of the 11th International Pathogenic Neisseria Conference. EDK, Paris, France.
|
| 24.
|
Lee, C. J.
1987.
Bacterial capsular polysaccharides biochemistry, immunity and vaccine.
Mol. Immunol.
24:1005-1019[CrossRef][Medline].
|
| 25.
|
Leib, S. L., and M. G. Tauber.
1999.
Pathogenesis of bacterial meningitis.
Infect. Dis. Clin. N. Am.
13:527-548[CrossRef][Medline].
|
| 26.
|
Leist, T. P.,
K. Frei,
S. Kam-Hansen,
R. M. Zinkernagel, and A. Fontana.
1988.
Tumor necrosis factor alpha in cerebrospinal fluid during bacterial, but not viral, meningitis. Evaluation in murine model infections and in patients.
J. Exp. Med.
167:1743-1748[Abstract/Free Full Text].
|
| 27.
|
Meda, L.,
S. Gasperini,
M. Ceska, and M. A. Cassatella.
1994.
Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by interferon.
Cell. Immunol.
57:448-461.
|
| 28.
|
Moller, B.,
S. C. Mogensen,
P. Wendelboe,
K. Bendtzen, and C. M. Petersen.
1991.
Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis.
J. Infect. Dis.
163:886-889[Medline].
|
| 29.
|
Mustafa, M. M.,
O. Ramilo,
K. D. Olsen,
P. S. Franklin,
E. J. Hansen,
B. Beutler, and G. H. McCracken.
1989.
Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis.
J. Clin. Investig.
84:1253-1259.
|
| 30.
|
Peltola, H.
1984.
Meningococcal disease: still with us.
Rev. Infect. Dis.
5:71-91.
|
| 31.
|
Ramilo, O.,
X. Saez-Llorens,
J. Mertsola,
H. Jafari,
K. D. Olsen,
E. J. Hansen,
M. Yoshinaga,
S. Ohkawara,
H. Nariuchi, and G. H. McCracken, Jr.
1990.
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation.
J. Exp. Med.
172:497-507[Abstract/Free Full Text].
|
| 32.
|
Raziuddin, S.,
M. E. el-Awad,
A. W. Telmesani,
N. E. Bilal, and M. al-Janadi.
1995.
CD4+ Th2 cell response cytokine production in bacterial meningitis.
J. Clin. Immunol.
5:338-348.
|
| 33.
|
Scapini, P.,
F. Calzetti, and M. A. Cassatella.
1999.
On the detection of neutrophil-derived vascular endothelial growth factor (VEGF).
J. Immunol. Methods
232:121-129[CrossRef][Medline].
|
| 34.
|
Seebach, J.,
D. Bartholdi,
K. Frei,
K. S. Spanaus,
E. Ferrero,
U. Widmer,
S. Isenmann,
R. M. Strieter,
M. Schwab, and H. Pfister.
1998.
Experimental Listeria meningoencephalitis: macrophage inflammatory protein-1 alpha and -2 are produced intrathecally and mediate chemotactic activity in cerebrospinal fluid of infected mice.
J. Immunol.
155:4367-4375[Abstract].
|
| 35.
|
Sierra, G. V.,
C. H. Campa, and M. Varcárcel.
1991.
Vaccine against group B N. meningitidis: protection trial and mass vaccination results in Cuba.
NIPH Ann.
14:195-210[Medline].
|
| 36.
|
Sierra, G. V.,
C. Campa,
L. García,
F. Sotolongo,
L. Izquierdo,
M. Valcárcel,
V. Casanueva,
M. Baró,
F. Leguen,
R. Rodríguez, and H. Terry.
1990.
Efficacy evaluation of the Cuban vaccine VA-MENGOC-BC® against disease caused by serogroup B Neisseria meningitidis, p. 129-134.
In
M. Achtman, K. Peter, and M. Christian (ed.), Proceedings of the Seventh International Pathogenic Neisseria Conference. Walter de Gruyter, Berlin, Germany.
|
| 37.
|
Spanaus, K. S.,
D. Nadal,
H. W. Pfister,
J. Seebach,
U. Widmer,
K. Frei,
S. Gloor, and A. Fontana.
1997.
C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro.
J. Immunol.
158:1956-1964[Abstract].
|
| 38.
|
Stephens, D. S.
1985.
Neisseria meningitidis.
Infect. Control
6:37-40[Medline].
|
| 39.
|
Tauber, M. G., and B. Moser.
1999.
Cytokines and chemokines in meningeal inflammation: biology and clinical implications.
Clin. Infect. Dis.
28:1-11[Medline].
|
| 40.
|
Tuomanen, E. I.,
K. Saukkonen,
S. Sande,
C. Cioffe, and S. D. Wright.
1989.
Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes.
J. Exp. Med.
170:959-969[Abstract/Free Full Text].
|
| 41.
|
Wang, P.,
P. Wu,
A. J. Anthes,
M. I. Siegel,
R. W. Egan, and M. M. Billah.
1994.
Interleukin-10 inhibits interleukin-8 production in human neutrophils.
Blood
83:2678-2683[Abstract/Free Full Text].
|
| 42.
|
Wyle, F. E.,
M. S. Artenstein,
B. L. Brandt,
E. C. Tramont,
D. L. Kasper,
P. L. Altieri,
S. L. Berman, and J. P. Lowenthal.
1972.
Immunological response in man to group B meningococcal polysaccharides vaccines.
J. Infect. Dis.
126:514-522[Medline].
|
Infection and Immunity, December 2000, p. 6917-6923, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tavano, R., Franzoso, S., Cecchini, P., Cartocci, E., Oriente, F., Arico, B., Papini, E.
(2009). The membrane expression of Neisseria meningitidis adhesin A (NadA) increases the proimmune effects of MenB OMVs on human macrophages, compared with NadA- OMVs, without further stimulating their proinflammatory activity on circulating monocytes. J. Leukoc. Biol.
86: 143-153
[Abstract]
[Full Text]
-
Hurtado-Nedelec, M., Chollet-Martin, S., Nicaise-Roland, P., Grootenboer-Mignot, S., Ruimy, R., Meyer, O., Hayem, G.
(2008). Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford)
47: 1160-1167
[Abstract]
[Full Text]
-
Polenghi, A., Bossi, F., Fischetti, F., Durigutto, P., Cabrelle, A., Tamassia, N., Cassatella, M. A., Montecucco, C., Tedesco, F., de Bernard, M.
(2007). The Neutrophil-Activating Protein of Helicobacter pylori Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. J. Immunol.
178: 1312-1320
[Abstract]
[Full Text]
-
Tavares, E., Minano, F. J., Maldonado, R., Dascombe, M. J.
(2006). Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E2. J. Leukoc. Biol.
80: 1375-1387
[Abstract]
[Full Text]
-
Plant, L., Wan, H., Jonsson, A.-B.
(2006). MyD88-Dependent Signaling Affects the Development of Meningococcal Sepsis by Nonlipooligosaccharide Ligands.. Infect. Immun.
74: 3538-3546
[Abstract]
[Full Text]
-
Gordon, J. R., Li, F., Zhang, X., Wang, W., Zhao, X., Nayyar, A.
(2005). The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. J. Leukoc. Biol.
78: 1265-1272
[Abstract]
[Full Text]
-
Krueger, G., Callis, K.
(2004). Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis. Arch Dermatol
140: 218-225
[Abstract]
[Full Text]
-
von Stebut, E., Metz, M., Milon, G., Knop, J., Maurer, M.
(2003). Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1alpha /beta released from neutrophils recruited by mast cell-derived TNFalpha. Blood
101: 210-215
[Abstract]
[Full Text]
-
Al-Mohanna, F., Saleh, S., Parhar, R. S., Collison, K.
(2002). IL-12-dependent nuclear factor-{kappa}B activation leads to de novo synthesis and release of IL-8 and TNF-{alpha} in human neutrophils. J. Leukoc. Biol.
72: 995-1002
[Abstract]
[Full Text]
-
Crepaldi, L., Silveri, L., Calzetti, F., Pinardi, C., Cassatella, M. A.
(2002). Molecular basis of the synergistic production of IL-1 receptor antagonist by human neutrophils stimulated with IL-4 and IL-10. Int Immunol
14: 1145-1153
[Abstract]
[Full Text]
-
Khan, A. Q., Shen, Y., Wu, Z.-Q., Wynn, T. A., Snapper, C. M.
(2002). Endogenous Pro- and Anti-Inflammatory Cytokines Differentially Regulate an In Vivo Humoral Response to Streptococcus pneumoniae. Infect. Immun.
70: 749-761
[Abstract]
[Full Text]
-
Brandtzaeg, P., Bjerre, A., Ovstebo, R., Brusletto, B., Joo, G. B., Kierulf, P.
(2001). Invited review: Neisseria meningitidis lipopolysaccharides in human pathology. Innate Immunity
7: 401-420
[Abstract]
-
Kolb-Maurer, A., Unkmeir, A., Kammerer, U., Hubner, C., Leimbach, T., Stade, A., Kampgen, E., Frosch, M., Dietrich, G.
(2001). Interaction of Neisseria meningitidis with Human Dendritic Cells. Infect. Immun.
69: 6912-6922
[Abstract]
[Full Text]
-
Crepaldi, L., Gasperini, S., Lapinet, J. A., Calzetti, F., Pinardi, C., Liu, Y., Zurawski, S., de Waal Malefyt, R., Moore, K. W., Cassatella, M. A.
(2001). Up-Regulation of IL-10R1 Expression Is Required to Render Human Neutrophils Fully Responsive to IL-10. J. Immunol.
167: 2312-2322
[Abstract]
[Full Text]